GLPGGALAPAGOS NV

Nasdaq glpg.com


$ 25.72 $ -0.12 (-0.46 %)    

Thursday, 20-Jun-2024 10:26:15 EDT
QQQ $ 485.10 $ -2.49 (-0.51 %)
DIA $ 389.83 $ 1.10 (0.28 %)
SPY $ 548.79 $ -0.63 (-0.11 %)
TLT $ 93.47 $ 0.07 (0.08 %)
GLD $ 218.42 $ 2.18 (1.01 %)
$ 25.84
$ 25.67
$ 0.00 x 0
$ 0.00 x 0
$ 25.67 - $ 25.72
$ 25.32 - $ 44.25
107,768
na
1.7B
$ 0.83
$ 7.27
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next gener...

 galapagos-and-blood-centers-of-america-collaborate-to-expand-galapagos-decentralized-car-t-manufacturing-network-in-the-us

BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product ...

 galapagos-q1-eps-140-vs-040-yoy-revenue-624-million-vs-586-million-yoy

Results from our continuing operationsTotal operating loss from continuing operations for the three months ended 31 March 2024 ...

 morgan-stanley-maintains-equal-weight-on-galapagos-maintains-38-price-target

Morgan Stanley analyst Judah Frommer maintains Galapagos (NASDAQ:GLPG) with a Equal-Weight and maintains $38 price target.

 galapagos-plans-clinical-and-translational-data-presentations-at-ebmt-congress-2024

Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL...

 galapagos-downgraded-pharma-firm-faces-uphill-battle-with-slow-pipeline-progress-analyst

BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded m...

 b-of-a-securities-downgrades-galapagos-to-underperform-lowers-price-target-to-31

B of A Securities analyst Jason Gerberry downgrades Galapagos (NASDAQ:GLPG) from Neutral to Underperform and lowers the pric...

 b-of-a-securities-downgrades-galapagos-to-underperform-lowers-price-target-to-31

B of A Securities analyst Jason Gerberry downgrades Galapagos (NASDAQ:GLPG) from Neutral to Underperform and lowers the pric...

 morgan-stanley-assumes-galapagos-at-equal-weight-announces-price-target-of-38

Morgan Stanley analyst Judah Frommer assumes Galapagos (NASDAQ:GLPG) with a Equal-Weight rating and announces Price Target o...

 earnings-scheduled-for-february-22-2024

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on reve...

 galapagos-to-present-new-preliminary-translational-data-and-previously-disclosed-data-from-euplagia-1-phase-12-study-at-the-european-society-for-blood-and-marrow-transplantation---8k

The preliminary translational data demonstrate that Galapagos’ differentiated point-of-care manufacturing platform offers the p...

 european-drugmaker-galapagos-collaborates-with-biotech-bridgene-biosciences-to-develop-cancer-treatments

On Wednesday, BridGene Biosciences Inc. announced a strategic collaboration and licensing agreement with Galapagos NV (NASDAQ: ...

 b-of-a-securities-maintains-neutral-on-galapagos-raises-price-target-to-44

B of A Securities analyst Jason Gerberry maintains Galapagos (NASDAQ:GLPG) with a Neutral and raises the price target from $...

 galapagos-transforms-into-biotech-innovator-sells-jyseleca-business-to-alfasigma-with-key-executive-transition

In connection with the transaction, Galapagos expects to realize substantial savings ranging between €150 million and €200 mill...